IMJUDO
tremelimumab
- Strength
- 25 mg/1.25mL
- Form
- Injection, Solution
- Class
- CTLA-4-directed Blocking Antibody
AstraZeneca Pharmaceuticals LP
Not stocked by us — reference only
tremelimumab
Listed by AstraZeneca Pharmaceuticals LP
| Dosage form | Injection, Solution |
|---|---|
| Route | Intravenous |
| Drug class | CTLA-4-directed Blocking Antibody |
| Approval route | BLA — biologic licence |
| NDC code | 0310-4535 |
| FDA application | BLA761289 |
| RxNorm concept | 2619317 |
| Package sizes listed | 1 |
| Marketed since | October 2022 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
tremelimumab
AstraZeneca Pharmaceuticals LP
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.